These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 34453698)

  • 1. Clinical and molecular characteristics of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer.
    Geng D; Guo Q; Huang S; Zhang H; Guo S; Li X
    Clin Transl Oncol; 2022 Feb; 24(2):379-387. PubMed ID: 34453698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions.
    Chen K; Pan G; Cheng G; Zhang F; Xu Y; Huang Z; Fan Y
    Thorac Cancer; 2021 Jan; 12(2):218-226. PubMed ID: 33210451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the Clinical Characteristics and Prognosis of Advanced Non-Small Cell Lung Cancer with Exon 20 Insertions.
    Wang H; Xu Y; Lin J; Huang Y
    Cancer Control; 2024; 31():10732748241262190. PubMed ID: 38857163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations.
    Yang GJ; Li J; Xu HY; Sun Y; Liu L; Li HS; Yang L; Zhang Y; Li GH; Wang Y
    Lung Cancer; 2021 Feb; 152():39-48. PubMed ID: 33341538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors.
    Lau SCM; Fares AF; Le LW; Mackay KM; Soberano S; Chan SW; Smith E; Ryan M; Tsao MS; Bradbury PA; Pal P; Shepherd FA; Liu G; Leighl NB; Sacher AG
    Clin Lung Cancer; 2021 Jul; 22(4):253-259. PubMed ID: 33582070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
    Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations.
    Hu M; Zhong C; Wang J; Chen J; Zhou T
    Front Immunol; 2024; 15():1399975. PubMed ID: 38774882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.
    Sa H; Shi Y; Ding C; Ma K
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7729-7742. PubMed ID: 37004599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors.
    Qin Y; Jian H; Tong X; Wu X; Wang F; Shao YW; Zhao X
    Mol Oncol; 2020 Aug; 14(8):1695-1704. PubMed ID: 32412152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation.
    Ma L; Diao B; Huang Z; Wang B; Yu J; Meng X
    Cancer Commun (Lond); 2021 Dec; 41(12):1314-1330. PubMed ID: 34699691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with
    Metro G; Baglivo S; Bellezza G; Mandarano M; Gili A; Marchetti G; Toraldo M; Molica C; Reda MS; Tofanetti FR; Siggillino A; Prosperi E; Giglietti A; Di Girolamo B; Garaffa M; Marasciulo F; Minotti V; Gunnellini M; Guida A; Sassi M; Sidoni A; Roila F; Ludovini V
    Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33946594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.
    Si J; Hao Y; Wei J; Xiang J; Xu C; Shen Q; Song Z
    BMC Pulm Med; 2023 May; 23(1):158. PubMed ID: 37147602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC; Jablons DM; Yang CT; You L
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors.
    Chen Q; Shang X; Liu N; Ma X; Han W; Wang X; Liu Y
    Front Immunol; 2022; 13():931718. PubMed ID: 35990690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.
    Yang G; Li J; Xu H; Yang Y; Yang L; Xu F; Xia B; Zhu VW; Nagasaka M; Yang Y; Li Y; Qiu W; Ying J; Ou SI; Wang Y
    Lung Cancer; 2020 Jul; 145():186-194. PubMed ID: 32336530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.
    Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X
    BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non-small cell lung cancer.
    Pan B; Liang J; Shi H; Rao K; Guo W; Zhan C
    Thorac Cancer; 2023 Nov; 14(33):3247-3258. PubMed ID: 37795778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
    Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
    Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.